Heparin Label Update Aims to Clarify Dosage Strength

|
Irvin Jackson

Add Your Comments

Federal drug regulators have ordered a warning label update for the blood thinner heparin, which is designed to better explain the drug’s dosage strengths. 

The FDA issued a drug safety communication on December 6, indicating that label changes will affect Heparain Lock Flush Solution, USP and Heparin Sodium Injection, USP.

The medications will be required to clearly stat the strength of the entire container, in addition to how much of the drug’s active ingredient is in a 1 milliliter (mL) dose.

Do You Know about…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION
Spinal-Cord-Stimulation-Lawsuit
Spinal-Cord-Stimulation-Lawsuit

Do You Know About…

Spinal Cord Stimulator lawsuits

Spinal cord stimulator lawsuits are being investigated for individuals who suffered unnecessary shocks, burns or other problems, often resulting in the need for additional surgery to remove the SCS.

Learn More
SEE IF YOU QUALIFY FOR COMPENSATION

The dosage strength on the old labels simply read: 5,000 USP units per mL. But the updated labels will read: 50,000 USP units per 10 mL (5,000 USP units per mL).

The FDA says the new labels will “eliminate the need for health care professionals to calculate the total amount of heparin medication in a product containing more than 1 mL, thereby reducing the risk of miscalculations that may result in medication errors.”

Concerns began surfacing about risks associated with heparin dosage labels in 2009. Manufacturers are required to have the new labels in place by May 1, 2013.

Irvin Jackson
Written by: Irvin Jackson

Senior Legal Journalist & Contributing Editor

Irvin Jackson is a senior investigative reporter at AboutLawsuits.com with more than 30 years of experience covering mass tort litigation, environmental policy, and consumer safety. He previously served as Associate Editor at Inside the EPA and contributes original reporting on product liability lawsuits, regulatory failures, and nationwide litigation trends.

Tags: Blood Thinner, Heparin, Heparin Recall
Image Credit: |

More Lawsuit Stories

0 Comments

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

Depo-Provera Lawsuit Settlement Agreement May Resolve Eligible Meningioma Claims in MDL
A tentative Depo-Provera lawsuit settlement has been announced, vacating the start of the first bellwether trial while details are finalized.
Lawsuit Alleges Spinal Cord Stimulator Shocks, Burns Caused by Manufacturing Defect
A spinal cord stimulator lawsuit claims that the Abbott Proclaim XR 5 system failed to treat a man’s chronic pain, instead leaving him with shocks and burning sensations.
Suboxone Dental Erosion Lawsuit Alleges Indivior Should Have Known About Tooth Decay Risks
A Suboxone dental erosion lawsuit filed by nine plaintiffs accuses the manufacturer of knowing the film strips caused severe tooth decay and other oral health problems, but failed to warn the medical community or patients.